Ed tablets fresh information.

NEW YORK (Reuters) -
Eli Lilly and Co on Tuesday said U.S.
regulators approved cialis tadalafil generic rezeptfrei
use of two low-dose forms of its
Cialis tadalafil pills
drug, offering greater convenience for
men expecting frequent sexual activity.

ADVERTISEMENT

The Indianapolis drugmaker said the once-daily
cialis soft uk, in dosages of 2.5 milligrams and 5 milligrams,
will allow men to attempt sexual activity any time between
doses.

“In clinical trials, when taken without restrictions on the
timing of sexual activity, Cialis for once daily use improved
erectile function over the course of therapy,” Lilly said in a
release.

The low-dose daily formulations, already approved in parts
of Europe, “may be most appropriate for men with erectile
tadalafil loc mx who anticipate more frequent sexual activity (e.g.
twice weekly),” Lilly said.

The company said the low-dose formulations provide “a new
option for men who may be looking for a dosing option that can
be taken without regard to timing of sexual activity.”

The treatment, which has global annual sales of $1.2
billion, has been available in the United States since 2003 in
dosages of 5 milligrams, 10 milligrams and 20 milligrams, and
taken as needed. Those dosages provide effectiveness for up to
36 hours.

Company spokeswoman Keri McGrath said no dosage forms of
the medicine, including the newly approved lower ones, are
appropriate for heart patients who take nitrates, including
nitroglycerin.

Members of the class of drugs to which Cialis belongs –
including Pfizer Inc's rival Viagra and GlaxoSmithKline Plc's
Levitra — can dangerously lower blood pressure when used
alongside nitrates.

The drugs, used by millions of men worldwide, also carry
new warnings about potential risk of sudden hearing loss.

Shares of Lilly were up $1.05, or 1.9 percent, to $55.60 in
morning trading on the New York Stock Exchange, in line with a
2 percent advance for the drug sector.

(Reporting by Ransdell Pierson, editing by Gerald E.
McCormick)

PARIS (Reuters) -
French customs officials have cialis tadalafil generic rezeptfrei

a shipment of 224,000 fake Viagra and Cialis anti-impotence
pills worth 2.4 million euros ($3.5 million), the Budget
Ministry said on Monday.

Tadalafil

The copies of the best-selling drugs were found on December
18 during a search at the French capital's main air hub at
Roissy, in a freight cargo on its way to Brazil from India.

“Branded Powergra and Erectalis, each box generic tadalafil softtabs
, in
fact, four tablets in the characteristic shape and color of
Viagra or Cialis pills,” Budget Minister Eric Werth's office,
which is also in charge of customs, said in a tadalafil
.

“The companies Pfizer and Eli Lilly, which respectively own
the Viagra and Cialis brands, quickly confirmed the counterfeit
nature of these products and the 224,000 pills were seized,”
Werth's office added.

LONDON (Reuters) -
A third of men with erectile dysfunction
could not perform after taking their first tablet of an
impotence drug and gave up sex entirely, according to a study
presented at the European Society of Sexual Medicine on
Tuesday.

The findings show the acquisto tadalafil
of the first-time pill for
erectile dysfunction patients who could tadalafil citrate
see better
results by switching tablets or increasing the dose, Dr. David
Edwards, a general practitioner in Oxfordshire in England, and
colleagues said.

Erectile dysfunction drugs like Pfizer Inc.'s Viagra, Eli
Lilly and Co's Cialis and Bayer AG's Levitra work by increasing
blood flow to the genitals.

The study presented at a buy and purchase viagra online
in Lisbon and funded by
Bayer looked at 631 men with an average age of 55 who had
erectile dysfunction. All had at some point taken a pill for
their condition, and 70 percent were still on some medication.

When the pills did not work the first time, 68 percent of
men reported a loss of self-esteem, 32 percent felt depressed
and 24 percent said they believed their condition could never
be treated.

One third simply did not return to their doctor to try an
alternative treatment after a failed attempt, something the
researchers said drugs tadalafil
the fact many men delay or ignore
treating their problem.

“These data confirm that men are still reluctant to seek
help for their erectile dysfunction and highlight the
importance of first-time success on improving aspects of
trattamento cronico tadalafil
,” the researchers wrote in an abstract.

(Reporting by Michael Kahn; Editing by Maggie Fox)

NEW YORK (Reuters) -
Eli Lilly and Co (LLY.N) said on
Tuesday chief executive Sidney Taurel will retire on March 31,
turning the reins over to Chief Operating Officer John
Lechleiter as the drugmaker prepares for tough times ahead.

The appointment of Lechleiter, 54, comes ahead of looming
patent expirations on three of Lilly's top drugs. The
CEO-designate earlier this month said the company will face
“its biggest challenge” ever as the drugs contend with cheaper
generics, but he said new Lilly products would help offset lost
revenue.

“My experience equips me to meet the company's biggest
challenge, which is to bring new molecules forward,” Lechleiter
said in an interview on Tuesday. He said he intends to give
Lilly scientists the breathing space needed for invention.

The 58-year-old Taurel's retirement and the selection of
Lechleiter to succeed him had been widely expected since
Lechleiter was promoted to COO in October 2005 and assumed ever
greater generic tadalafil softtabs
and a higher profile with the
Indianapolis-based company.

Lechleiter came to Lilly in 1979 as an organic chemist and
over the next 15 years took a number of senior executive roles
in research and development, including stints in England and
Europe. In 2004, the year before he became Taurel's top deputy,
he was named head of Lilly's pharmaceutical operations.

Lechleiter said Lilly's future success could hinge in part
on its ability to create medicines tailored for the genetic
makeup of patients, a discipline Lilly calls “tailored
cheap tadalafil
.”

“We want to make sure the right patients get the right dose
of the right medicine at the right time,” Lechleiter said.

Lehman Brothers analyst Tony Butler predicted Lechleiter
will continue Lilly's pattern of forging partnerships with
other drugmakers — the kinds of deals that have brought it the
widely used impotence treatment Cialis, and Byetta for diabetes
– while coaxing important new drugs from Lilly's laboratories.

HIS FORTE

“Tadalafil for sale
how to make a drug and how to deal with
regulators have been his forte and will serve him well as CEO,”
said Butler, who noted Lechleiter headed regulatory affairs for
Lilly in the mid-1990s before taking charge of pharmaceutical
operations.

“Over the last decade, Lilly has been one of the most
innovative companies, producing novel drugs and not losing
sight about the importance of research, and that's what John
brings to the table,” Butler said.

Taurel joined Lilly as a marketing associate in 1971 and
took the helm of the company in July 1998. He has been chairman
since early 1999. He will continue as board chairman until the
end of 2008, Lilly said.

Under Taurel, Lilly has been recognized for its research,
developing medicines that have become blockbuster products,
including schizophrenia treatment Zyprexa, anti-depressant
Cymbalta and chemotherapy agent Gemzar.

But Lechleiter acknowledged in an earlier Reuters interview
this month that it will be difficult for Lilly to make up the
revenue shortfall when those three drugs face patent
expirations between 2010 and 2012.

“There's no question we will face the biggest challenge of
our history at the beginning of the next decade, but we're
confident we can meet that challenge based on new products
being launched before and during that period,” he said.

Toward that end, Lechleiter said Lilly aims to launch two
new drugs per year, on average, beginning in 2011, increasing
to three per year by 2014. It aims to move at least 10
additional drugs into late-stage studies by 2011.

The company also has financial strength to license or buy
more drugs, said Lechleiter.

At a Lilly meeting with investors and analysts in New York
on December 6, Taurel remained largely out of the spotlight,
allowing Lechleiter to take the lead in describing company
strategy.

Lilly shares traded up almost 1 percent to $53.67 in
over the counter erectile dysfunction medication trading Tuesday on the New York Stock Exchange,
in line with gains for the drug sector.

(Reporting by Ransdell Pierson; Editing by Brian Moss and
John Wallace)